nach oben

Erschienen in:

01.12.2012 | TASK FORCE REPORT

Indian Society of Gastroenterology consensus on ulcerative colitis

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

In 2010, the Indian Society of Gastroenterology’s Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on ulcerative colitis. This consensus, produced through a modified Delphi process, reflects our current understanding of the definition, diagnostic work up, treatment and complications of ulcerative colitis. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.

Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31: doi:10.1007/s12664-012-0258-1.

Linstone H, Turoff M. The Delphi method: techniques and application. http://www.is.njit.edu/pubs/delphibook/. Accessed on August 15, 2012.

Periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.

Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef

Khosla SN, Girdhar NK, Lal S, Mishra DS. Epidemiology of ulcerative colitis and select general population of northern India. J Assoc Physicians India. 1986;34:405–7.PubMed

Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587–90.PubMedCrossRef

Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–9.PubMedCrossRef

Lok KH, Hung HG, Ng CH, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406–10.PubMedCrossRef

Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009;104:647–54.PubMedCrossRef

10.

Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 1995;30 Suppl 8:1–4.

11.

Lee YM, Fock K, See SJ, Ng TM, Khor C, Teo EK. Racial differences in the prevalence of ulcerative colitis and Crohn’s disease in Singapore. J Gastroenterol Hepatol. 2000;15:622–5.PubMedCrossRef

12.

Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002;35:144–8.PubMedCrossRef

13.

Tan YM, Goh KL. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation among Malaysian patients. World J Gastroenterol. 2005;11:5859–62.PubMed

14.

Probert CS, Mayberry JF, Mann R. Inflammatory bowel disease in the rural Indian subcontinent: a survey of patients attending mission hospitals. Digestion. 1990;47:42–6.PubMedCrossRef

15.

Maroo MK, Nag NK, Sortur SV, Patil RS. Ulcerative colitis in Southern Maharashtra. J Indian Med Assoc. 1974;63:350–4.PubMed

16.

Tandon BN, Mathur AK, Mohapatra LN, Tandon HD, Wig KL. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in northern India. Gut. 1965;6:448–53.PubMedCrossRef

17.

Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol. 2007;26:285–9.PubMed

18.

Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut. 1994;35:696–700.PubMedCrossRef

19.

Jiang L, Xia B, Li J, et al. Risk factors for ulcerative colitis in a Chinese population: an age-matched and sex-matched case–control study. J Clin Gastroenterol. 2007;41:280–4.PubMedCrossRef

20.

Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol. 1995;30 Suppl 8:5–8.

21.

Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006;12:1146–51.PubMedCrossRef

22.

Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34:1547–51.PubMedCrossRef

23.

Probert CS, Jayanthi V, Pinder D, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33:687–93.PubMedCrossRef

24.

Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first and second-generation South Asians in Leicester (1991–1994). Am J Gastroenterol. 1999;94:2918–22.PubMed

25.

Jayanthi V, Probert CS, Pollock DJ, et al. Low incidence of ulcerative colitis and proctitis in Bangladeshi migrants in Britain. Digestion. 1992;52:34–42.PubMedCrossRef

26.

Probert CS, Jayanthi V, Mayberry JF. Inflammatory bowel disease in Indian migrants in Fiji. Digestion. 1991;50:82–4.PubMedCrossRef

27.

Rajput HI, Seebaran AR, Desai Y. Ulcerative colitis in the Indian population of Durban. S Afr Med J. 1992;81:245–8.PubMed

28.

Kochhar R, Mehta SK, Nagi B, Bhatia V, Goenka MA, Malik AK. Extraintestinal manifestations in idiopathic ulcerative colitis. Indian J Gastroenterol. 1991;10:88–9.PubMed

29.

Pokharna RK, Kabra PK, Sharma P, Kochar DK. Extraintestinal manifestations of idiopatic ulcerative colitis in north western India. Indian J Gastroenterol. 2004;123:89–90.

30.

Chandrasekaran AN, Porkodi R, Madhavan R, Sambandam PR, Jayanthi V, Ramathilagam B. Spectrum of clinical and immunological features of systemic rheumatic disorders in a referral hospital in south India: arthritis in ulcerative colitis. J Indian Rheumat Assoc. 1995;3:43–7.

31.

Habeeb MA, Rajalingam R, Dhar A, Kumar A, Sharma MP, Mehra NK. HLA association and occurrence of autoantibodies in Asian patients with ulcerative colitis. Am J Gastroenterol. 1997;92:772–6.PubMed

32.

Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.PubMedCrossRef

33.

Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16.

34.

Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis. 2008;2:1–23.CrossRef

35.

Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–68.PubMedCrossRef

36.

Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc. 1983;29:195–7.PubMedCrossRef

37.

Dunzendorfer T, Kasznica J. Amebic and/or ulcerative colitis? Gastrointest Endosc. 1998;48:450–1.PubMedCrossRef

38.

Misra SP, Misra V, Dwivedi M, Singh PA. Colonic tuberculosis mimicking ulcerative colitis. J Assoc Physicians India. 1998;46:309–10.PubMed

39.

Chodos JE. Campylobacter infection mimicking ulcerative colitis. NY State J Med. 1986;86:22–3.

40.

Ibrahim TM, Iheonunekwu N, Gill V, Vantapool H. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005;54:210–12.PubMedCrossRef

41.

Mann EA, Saeed SA. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol. 2012;28:24–9.PubMedCrossRef

42.

Khuroo MS, Mahajan R, Zargar SA, et al. The colon in shigellosis: serial colonoscopic appearances in Shigella dysenteriae I. Endoscopy. 1990;22:35–8.PubMedCrossRef

43.

Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993;16:26–30.PubMedCrossRef

44.

Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–60.

45.

Banerjee D, Deb R, Dar L, et al. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44:325–31.PubMedCrossRef

46.

Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–8.PubMedCrossRef

47.

Vaishnavi C, Kochhar R, Bhasin D, Thennarasu K, Singh K. Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol. 2003;24:13–6.PubMed

48.

Kashyap B, Sinha S, Das S, Rustagi N, Jhamb R. Efficiency of diagnostic methods for correlation between prevalence of enteric protozoan parasites and HIV/AIDS status––an experience of a tertiary care hospital in East Delhi. J Parasit Dis. 2010;34:63–7.PubMedCrossRef

49.

Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis. 2010;23:500–4.PubMedCrossRef

50.

Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25–9.PubMedCrossRef

51.

Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol. 2011;30:245–54.PubMedCrossRef

52.

Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–7.PubMedCrossRef

53.

Sung JJY, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183–93.PubMedCrossRef

54.

Schusselé Filliettaz S, Juillerat P, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009;41:218–26.PubMedCrossRef

55.

Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16:2600–3.PubMedCrossRef

56.

Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.PubMedCrossRef

57.

Kochhar R, Goenka MK, Kaushik SP, Gupta NM, Nagi B, Mehta SK. Colorectal carcinoma in Indian patients with idiopathic ulcerative colitis. Eur J Cancer Prev. 1992;1:293–6.PubMedCrossRef

58.

Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–9.PubMedCrossRef

59.

Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17:1008–14.PubMedCrossRef

60.

Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.PubMedCrossRef

61.

Naber AHJ, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003;61:105–10.PubMed

62.

Thia KT, Loftus EV Jr, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257–64.PubMedCrossRef

63.

Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol. 2009;28:143–6.PubMedCrossRef

64.

Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther. 2006;24 Suppl 3:41–4.

65.

Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263–76.PubMedCrossRef

66.

Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.PubMedCrossRef

67.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.

68.

Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663–8.PubMedCrossRef

69.

D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079–82.PubMed

70.

Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis. 1998;4:79–83.PubMedCrossRef

71.

Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left -sided ulcerative colitis. Gastroenterology. 1988;94:1075–9.PubMed

72.

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):D000544.

73.

Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;1:1094–6.PubMedCrossRef

74.

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.

75.

Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1–8.PubMedCrossRef

76.

Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902.PubMedCrossRef

77.

Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.PubMed

78.

Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRef

79.

Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J. 1962;2:1708–11.PubMedCrossRef

80.

Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, Salazopyrin and topicalhydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut. 1960;1:217–22.PubMedCrossRef

81.

Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.PubMedCrossRef

82.

Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12:40–1.PubMedCrossRef

83.

Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.PubMedCrossRef

84.

Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;i:1067–70.CrossRef

85.

Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–10.PubMedCrossRef

86.

Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.PubMedCrossRef

87.

Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478.

88.

Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512–8.PubMedCrossRef

89.

Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717–22.PubMed

90.

Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455–61.PubMedCrossRef

91.

Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37:270–4.PubMedCrossRef

92.

Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–6.PubMedCrossRef

93.

Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22:79–81.PubMed

94.

Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006;12:7332–6.PubMed

95.

Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology. 2004;127:1558–64.PubMedCrossRef

96.

Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol. 2010;27:1046–9.PubMedCrossRef

97.

Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2002;24:353–9.PubMedCrossRef

98.

Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D. TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers. 2009;27:231–8.PubMed

99.

Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.PubMedCrossRef

100.

Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.PubMedCrossRef

101.

Sood A, Midha V, Sood N, et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analysis of 24 cases. Indian J Gastroenterol. 2008;27:232–5.PubMed

102.

Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3):CD005112.

103.

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef

104.

Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.PubMedCrossRef

105.

Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59:C4480.PubMed

106.

Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974–6.PubMed

107.

Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13:1453–4.PubMedCrossRef

108.

Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15:89–102.PubMed

109.

Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010;16:507–11.PubMed

110.

Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.PubMedCrossRef

111.

Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011;46:855–61.PubMedCrossRef

112.

Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5:39.PubMedCrossRef

113.

Cima RR. Timing and indications for colectomy in chronic ulcerative colitis: Surgical consideration. Dig Dis. 2010;28:501–7.PubMedCrossRef

114.

Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut. 2011;60:130–3.PubMedCrossRef

115.

Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60:3–9.PubMedCrossRef

116.

Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.PubMedCrossRef

117.

Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956–62.PubMedCrossRef

118.

Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol. 2009;3:325–7.PubMedCrossRef

119.

Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335–40.PubMedCrossRef

120.

Rao YG, Saxena R, Sahni P, Pande GK, Chattopadhyay TK. Functional outcome and patient satisfaction after ileal pouch anal anastomosis for ulcerative colitis in a developing country. Trop Gastroenterol. 2002;23:66–9.PubMed

121.

Somashekar U, Gupta S, Soin A, Nundy S. Functional outcome and quality of life following restorative proctocolectomy for ulcerative colitis in Indians. Int J Colorectal Dis. 2010;25:967–73.PubMedCrossRef

122.

Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol. 1999;94:1746–50.PubMedCrossRef

123.

Vleggaar FP, Lutgens MW, Claessen MM. Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26 Suppl 2:47–52.

124.

Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005;17:1317–24.PubMedCrossRef

125.

Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51 Suppl 5:V10–12.

126.

Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.PubMedCrossRef

127.

Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465–73.PubMedCrossRef

128.

Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10.PubMedCrossRef

129.

Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–65.PubMedCrossRef

130.

Navaneethan U, Shen L, Venkatesh PG, et al. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011;5:415–22.PubMedCrossRef

131.

Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104:639–46.PubMedCrossRef

132.

Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–6.PubMed

133.

Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004;23:161–70.PubMedCrossRef

134.

Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F. Milk tolerance in adults with ulcerative colitis. Am J Gastroenterol. 1994;89:872–7.PubMed

135.

Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot. 2011;74:801–11.PubMedCrossRef

136.

Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008;53:1278–84.PubMedCrossRef

137.

Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–9.PubMedCrossRef

138.

Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):CD005573.

139.

Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010;44:565–71.PubMedCrossRef

140.

Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRef

141.

Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–9.PubMedCrossRef

142.

Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–7.PubMedCrossRef

143.

Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol. 2006;5:187–9.PubMed

144.

Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968;1:117–8.PubMedCrossRef

145.

Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113–23.PubMedCrossRef

146.

Schirbel A, Sturm A. Imaging in inflammatory bowel disease: mucosal healing in ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012; May 28. [Epub ahead of print].

147.

Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004;20 Suppl 4:97–101.PubMedCrossRef

148.

Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008;14:4434–9.PubMedCrossRef

149.

Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis. 2007;13:1293–8.PubMedCrossRef

150.

Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008;6:1225–30.PubMedCrossRef

151.

Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731–6.PubMedCrossRef

152.

Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis? Inflamm Bowel Dis. 2008;14 Suppl 2:S238–9.PubMedCrossRef

153.

Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther. 2002;16 Suppl 4:21–4.PubMedCrossRef

154.

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.

Titel: Indian Society of Gastroenterology consensus on ulcerative colitis
Publikationsdatum: 01.12.2012
Erschienen in: Indian Journal of Gastroenterology / Ausgabe 6/2012
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI: https://doi.org/10.1007/s12664-012-0259-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Giant staghorn common bile duct calculus

Hepatitis B and C co-infection in HIV patients

Pseudolesion in a patient with superior vena cava syndrome

Prevalence and patterns of diverticulosis in patients undergoing colonoscopy in a southern Indian hospital

Systemic amyloidosis masquerading as iron deficiency anemia